AGIO
Price
$31.86
Change
-$0.41 (-1.27%)
Updated
Mar 4, 12:05 PM EST
59 days until earnings call
DNLI
Price
$20.99
Change
+$0.13 (+0.62%)
Updated
Mar 4, 1:14 PM EST
59 days until earnings call
Ad is loading...

AGIO vs DNLI ᐉ Comparison: Which is Better to Invest?

Header iconAGIO vs DNLI Comparison
Open Charts AGIO vs DNLIBanner chart's image
Agios Pharmaceuticals
Price$31.86
Change-$0.41 (-1.27%)
Volume$100
CapitalizationN/A
Denali Therapeutics
Price$20.99
Change+$0.13 (+0.62%)
Volume$503
CapitalizationN/A
View a ticker or compare two or three
AGIO vs DNLI Comparison Chart

Loading...

AGIODaily Signal changed days agoGain/Loss if shorted
 
Show more...
DNLIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AGIO vs. DNLI commentary
Mar 04, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGIO is a Hold and DNLI is a StrongSell.

COMPARISON
Comparison
Mar 04, 2024
Stock price -- (AGIO: $32.27 vs. DNLI: $20.86)
Brand notoriety: AGIO and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGIO: 95% vs. DNLI: 109%
Market capitalization -- AGIO: $1.81B vs. DNLI: $2.9B
AGIO [@Biotechnology] is valued at $1.81B. DNLI’s [@Biotechnology] market capitalization is $2.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $550.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.62B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGIO’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • AGIO’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, AGIO is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGIO’s TA Score shows that 6 TA indicator(s) are bullish while DNLI’s TA Score has 5 bullish TA indicator(s).

  • AGIO’s TA Score: 6 bullish, 4 bearish.
  • DNLI’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, AGIO is a better buy in the short-term than DNLI.

Price Growth

AGIO (@Biotechnology) experienced а -2.18% price change this week, while DNLI (@Biotechnology) price change was +23.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.37%. For the same industry, the average monthly price growth was +19.14%, and the average quarterly price growth was +52.89%.

Reported Earning Dates

AGIO is expected to report earnings on May 02, 2024.

DNLI is expected to report earnings on May 02, 2024.

Industries' Descriptions

@Biotechnology (+4.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for AGIO with price predictions.
OPEN
A.I.dvisor published
a Summary for DNLI with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
DNLI($2.9B) has a higher market cap than AGIO($1.81B). AGIO YTD gains are higher at: 44.903 vs. DNLI (-2.796). DNLI has higher annual earnings (EBITDA): -179.97M vs. AGIO (-384.86M). DNLI has more cash in the bank: 1.04B vs. AGIO (777M). DNLI has less debt than AGIO: DNLI (52.2M) vs AGIO (72M). DNLI has higher revenues than AGIO: DNLI (331M) vs AGIO (26.8M).
AGIODNLIAGIO / DNLI
Capitalization1.81B2.9B62%
EBITDA-384.86M-179.97M214%
Gain YTD44.903-2.796-1,606%
P/E RatioN/A62.89-
Revenue26.8M331M8%
Total Cash777M1.04B75%
Total Debt72M52.2M138%
FUNDAMENTALS RATINGS
AGIO vs DNLI: Fundamental Ratings
AGIO
DNLI
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
80
Overvalued
PROFIT vs RISK RATING
1..100
10093
SMR RATING
1..100
9690
PRICE GROWTH RATING
1..100
3744
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGIO's Valuation (48) in the Biotechnology industry is in the same range as DNLI (80). This means that AGIO’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's Profit vs Risk Rating (93) in the Biotechnology industry is in the same range as AGIO (100). This means that DNLI’s stock grew similarly to AGIO’s over the last 12 months.

DNLI's SMR Rating (90) in the Biotechnology industry is in the same range as AGIO (96). This means that DNLI’s stock grew similarly to AGIO’s over the last 12 months.

AGIO's Price Growth Rating (37) in the Biotechnology industry is in the same range as DNLI (44). This means that AGIO’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (96) in the Biotechnology industry is in the same range as AGIO (100). This means that DNLI’s stock grew similarly to AGIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGIODNLI
RSI
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bullish Trend 7 days ago
72%
Bullish Trend 4 days ago
78%
MACD
ODDS (%)
Bullish Trend 6 days ago
71%
Bullish Trend 4 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
77%
Advances
ODDS (%)
Bullish Trend 11 days ago
72%
Bullish Trend 11 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 5 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
88%
Aroon
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
82%
View a ticker or compare two or three
Ad is loading...
AGIODaily Signal changed days agoGain/Loss if shorted
 
Show more...
DNLIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PBQAX24.230.35
+1.47%
PGIM Jennison Blend A
FWMIX60.980.64
+1.06%
American Funds Washington Mutual F3
RTNAX11.280.11
+0.98%
Russell Inv Tax-Managed Intl Eq A
VGSCX30.440.29
+0.96%
Virtus Duff & Phelps Glb Rl Estt Secs C
SCETX7.840.03
+0.38%
Virtus Ceredex Small-Cap Value Eq I

AGIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGIO has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if AGIO jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGIO
1D Price
Change %
AGIO100%
-0.15%
CRSP - AGIO
54%
Loosely correlated
-0.56%
BEAM - AGIO
53%
Loosely correlated
+0.89%
RARE - AGIO
53%
Loosely correlated
+3.81%
NTLA - AGIO
52%
Loosely correlated
+1.68%
ALNY - AGIO
49%
Loosely correlated
+1.01%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been closely correlated with BEAM. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+5.46%
BEAM - DNLI
68%
Closely correlated
+0.89%
NTLA - DNLI
63%
Loosely correlated
+1.68%
JANX - DNLI
61%
Loosely correlated
-1.47%
XNCR - DNLI
53%
Loosely correlated
+3.79%
RARE - DNLI
51%
Loosely correlated
+3.81%
More